Trials / Conditions / BRCA2 Gene Mutation

BRCA2 Gene Mutation

23 registered clinical trials studyying BRCA2 Gene Mutation — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alter NCT06392841	Qian Qin	Phase 2
Recruiting	TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention NCT04294927	University Medical Center Nijmegen	N/A
Active Not Recruiting	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response NCT04030559	Marc Dall'Era, MD	Phase 2
Active Not Recruiting	Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cance NCT03943173	M.D. Anderson Cancer Center	EARLY_Phase 1
Terminated	Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Pros NCT03442556	University of Washington	Phase 2
Completed	Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian NCT03552471	Ohio State University Comprehensive Cancer Center	Phase 1
Completed	Usefulness of Video-Based Intervention in Helping Participants Encourage Their Families to Get Tested for BRCA NCT05264532	Ohio State University Comprehensive Cancer Center	N/A
Active Not Recruiting	Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Insta NCT03428802	Rutgers, The State University of New Jersey	Phase 2
Completed	Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tu NCT02953457	Roswell Park Cancer Institute	Phase 2
Suspended	Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) NCT02993068	M.D. Anderson Cancer Center	N/A
Completed	Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer NCT03377556	SWOG Cancer Research Network	Phase 2
Withdrawn	Pancreatic Cancer Screening of High-Risk Individuals in Arkansas NCT02309632	University of Arkansas	N/A
Unknown	The Link Between BRCA Mutation and Endothelial Function NCT02474264	Rabin Medical Center	N/A
Unknown	Cancer Prevention in Women With a BRCA Mutation NCT02225015	Women's College Hospital	Phase 1
Active Not Recruiting	Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers NCT02321228	University Medical Center Nijmegen	N/A
Active Not Recruiting	Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations i NCT02286687	M.D. Anderson Cancer Center	Phase 2
Completed	A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Ca NCT02197000	Rabin Medical Center	N/A
Active Not Recruiting	Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Sy NCT02194387	M.D. Anderson Cancer Center	N/A
Completed	Prospective Research of Outcomes After Salpingo-oophorectomy NCT01948609	University of California, San Francisco	—
Terminated	A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Bre NCT01905592	Tesaro, Inc.	Phase 3
Unknown	Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Brea NCT01907438	Hadassah Medical Organization	—
Completed	Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer NCT01975363	Ohio State University Comprehensive Cancer Center	N/A
Completed	ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer NCT01009788	Steven J Isakoff, MD, PhD	Phase 2